IRVINE, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in May. The first conference is the Deutsche Bank 39th Annual Health Care Conference in Boston, MA.
|Event:||Deutsche Bank 39th Annual Health Care Conference|
|Date:||Thursday, May 8, 2014|
|Time:||10:00 a.m. ET / 7:00 a.m. PT|
|Endologix Participants:||Shelley Thunen|
The second conference is the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV.
|Event:||Bank of America Merrill Lynch 2014 Health Care Conference|
|Date:||Thursday, May 15, 2014|
|Time:||11:20 a.m. PT / 2:20 p.m. ET|
|Endologix Participant:||John McDermott|
Audio webcasts of the Company's presentations at the Deutsche Bank 39th Annual Health Care Conference and the Bank of America Merrill Lynch 2014 Health Care Conference will be available by visiting the investor relations section of Endologix's website at www.endologix.com. Replays of the presentations will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Shelley Thunen, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020Source:Endologix